Abstract:Recently, gene therapy has been become a promising approach to cure hemophilia A, a most common recessive bleeding disease. The aim of this study was to determine the perspective of lentiviral vector in hemophilia A gene therapy in vitro and in NOD/SCID mice. Lentivirus transfer vector pXZ9/BDDFVIII containing human B-domain-deleted Factor VIII-IRES-eGFP coding sequence and mock control pXZ9 were constructed. Lentivirus was prepared by co-transfecting 3 plasmids into 293FT cells. 293FT, HLF, human bone marrow mesenchymal stem cells and Chang-liver cells were transfected with the prepared virus. Coagulant activity of human FVIII, human FVIII antigen, human FVIII mRNA transcription and genomic integration were assayed by ELISA, one-step method, RT-PCR and PCR after infection. Lentiviral particles were concentrated by ultracentrifugation and NOD/SCID mice were transfected via portal vein injection. Human FVIII antigen in mouse blood plasma was analyzed by ELISA. eGFP expression was observed by fluorescent microscopy and human FVIII transcription in mouse liver was analyzed by RT-PCR at one month after transduction. The results showed that the high titer of recombinant virus was prepared and used to efficiently transduce the target cells in vitro. At 72 h after transfection, high levels of FVIII activity and FVIII antigen were detected. Human FVIII gene transcription could be detected in the liver of NOD/SCID mice received lentiviral particles carrying FVIII gene. Mouse hepatocytes were transfected with recombinant lentivirus efficiently in vivo. Human FVIII level in mouse blood plasma reached to (49 ± 6) mU, (54 ± 8) mU and (23 ± 4) mU at 72 h, one week and one month after transfection respectively. It is concluded that the lentiviral particles carrying BDDhFVIII gene can high efficiently transfect the target cells both in vitro and in vivo, and the transfected target cells can secrete hFVIII efficiently. The sustained expression of human FVIII in NOD/SCID mice is observed after lentivirus transfection via portal vein injection.

Half-Life Extension Enhances Drug Efficacy in Adeno-Associated Virus Delivered Gene Therapy

New intranasal and injectable gene therapy for healthy life extension

Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins

Enhanced Gene Transfection Efficacy and Safety Through Granular Hydrogel Mediated Gene Delivery Process

Half-life extended biotherapeutics

Engineering a Pharmacologically Superior Form of Granulocyte-Colony-stimulating Factor by Fusion with Gelatin-Like-protein Polymer.

Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.

Albumin-binding as a universal strategy for half-life extension

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Simple improvements in vector design afford substantial gains in AAV delivery of aggregation-slowing Aβ variants

New Directions for Half-Life Extension of Protein Therapeutics: the Rise of Antibody Fc Domains and Fragments

Sustaining Expression of B Domain-Deleted Human Factor VIII Mediated by Using Lentiviral Vectors in NOD/SCID Mouse.

Site-Specific PEGylated Adeno-Associated Viruses with Increased Serum Stability and Reduced Immunogenicity.

Half-life extension using serum albumin-binding DARPin® domains

Improved Inhibition of Tumor Growth by Diabody-Drug Conjugates via Half-Life Extension

Adeno-associated virus vector as a platform for gene therapy delivery

Therapeutic strategy for Fabry disease by intravenous administration of adeno-associated virus 9 in a symptomatic mouse model

Adeno-associated virus as a delivery vector for gene therapy of human diseases

Generation of targeted adeno-associated virus (AAV) vectors for human gene therapy.

Half‐life extension of single‐domain antibody–drug conjugates by albumin binding moiety enhances antitumor efficacy

Molecular camouflage by a context-specific hydrogel as the key to unlock the potential of viral vector gene therapy